Selank dosage: the honest answer to “how much” for an unapproved peptide

“How much Selank” is a fair question with an uncomfortable answer: nobody can give you an FDA-validated dose, because Selank is not an FDA-approved drug. It is a Russian-developed anxiolytic peptide — a synthetic analog of the immune peptide tuftsin — used in Russia mostly as a nasal spray, and sold in the United States only as an unapproved “research peptide.” This page describes the dosing that actually appears in the limited literature and in user practice, and is explicit at every step that those are reported numbers, not a protocol. For the underlying pharmacology and the quality of the human studies, start with our Selank evidence review.

Why there is no “standard” Selank dose

Dosing standards come from one place: a regulatory approval process that ties a number to a diagnosis, a label, controlled trials, and a measured outcome. Selank has never been through that process in the United States. It is reported to have completed Phase III testing in Russia and is treated as a marketed anxiolytic there, but in the U.S. it sits entirely outside the framework that governs anxiety medications.^[1] Independent Western pharmacology reviewers have noted that it remains poorly studied yet is sold to U.S. consumers as a supplement despite not being an approved drug.^[2]Practically, that means every Selank “dose” circulating online is a convention borrowed from Russian practice and vendor instruction sheets — useful to understand, but categorically different from a figure printed on an approved drug label.

The form: why Selank is a nasal spray

Selank is almost always given intranasally, and that is not arbitrary. Like most peptides, it would be largely destroyed by stomach acid and digestive enzymes if swallowed, which rules out a practical oral tablet. Comparative distribution work in animals — which tracked the peptide through the body after intraperitoneal, intranasal, intragastric and intravenous routes — found that intranasal delivery was the optimal way to get the molecule into the central nervous system, the compartment where an anxiolytic needs to act.^[3] Intranasal Selank has also been shown to reach the brain functionally, for example regulating BDNF expression in the rat hippocampus after nasal dosing.^[4] So the “nasal spray” format isn’t a gimmick; it reflects the route the research actually used.

A second reason the nasal route dominates is Selank’s short biological life. As a small peptide it is cleared quickly, which is part of why dosing is described as a spray taken one or more times a day rather than a once-weekly depot. That short half-life is a recurring theme in the peptide literature and is one practical argument the nasal-spray format is built around — frequent, low-volume intranasal dosing rather than a single long-acting shot.

The doses reported in the literature and in practice

In the published Russian clinical work, Selank was studied as a short course of an intranasal solution in anxious patients. The clearest example is a study in 62 patients with generalized anxiety disorder and neurasthenia, in which Selank was compared against the benzodiazepine medazepam and produced a similar anxiolytic effect, with added anti-asthenic activity.^[5] The defining features of that clinical use, as reported, were that it was intranasal and time-limited — a defined treatment course measured in days to a couple of weeks, not an open-ended daily habit.

The numbers most often circulated by U.S. vendors and users describe a nasal solution dosed by the microgram-per-kilogram or by total daily micrograms, split across the day, for a course on the order of one to two weeks. We deliberately do not headline a single “correct” figure, because there isn’t one to validate: the precise concentrations and microgram totals quoted across sources vary, none is tied to a U.S. label, and several derive from product sheets rather than trials. The honest, load-bearing facts are the shape of the dosing — intranasal, divided through the day, given as a short course — rather than any exact milligram you could treat as a prescription.

What “N-acetyl Selank amidate” actually is

Searches for “N-acetyl Selank dosage” are really asking about a chemically modified variant of the same heptapeptide. Adding an acetyl group at one end and an amide at the other is a standard medicinal-chemistry move to slow enzymatic breakdown — the goal is a molecule that survives a little longer than plain Selank. Vendors sell it as “more stable,” and that chemistry is real. What is not real is the implication that it comes with its own separately proven, separately approved dose. There is no body of controlled human trials defining a regimen for the acetylated-amidated form specifically; it is dosed by analogy to the nasal solution above, and it carries the same regulatory status — unapproved. Treat “N-acetyl Selank amidate” as a formulation tweak sold in the same gray market, not as an upgraded drug with upgraded evidence.

What’s in the bottle matters as much as the number

Even a perfectly chosen figure is only meaningful if the spray contains what its label claims. Because Selank is dispensed outside the prescription and compounding-pharmacy system, the concentration, purity and identity of a given nasal solution carry no pharmaceutical-grade guarantee. A “dose” calculated from a vendor’s stated micrograms quietly assumes that vendor measured and labeled the peptide accurately — an assumption the unregulated market does not earn by default. Stacking a circulated, unproven dose on top of a product of unknown content widens the uncertainty rather than narrowing it. If you are weighing Selank despite all of this, our guide on where to get peptides safely covers how to reduce (not eliminate) that risk, and our peptide therapy cost breakdown explains why the cheapest vial is often the one whose contents you can least trust.

Safety notes that bear on dosing

Selank’s reported attraction is calm without the heavy sedation, memory fog, or dependence that define benzodiazepines — a profile that, if it holds, removes some of the dose-escalation pressure those drugs create. But that profile rests on the same handful of small, uncontrolled Russian trials, and should be treated as preliminary rather than as a blanket green light. There is no large human safety database, no characterized maximum tolerated dose, and at least one preclinical signal — anticoagulant (anti-clotting) activity among related peptides — that has not been worked out in people. Those gaps are exactly why “more is better” reasoning is misplaced here: without dose-response safety data, pushing the number higher is guessing, not optimizing. The full safety picture is in the evidence review.

Where Selank sits among the peptides people stack

Selank is usually discussed alongside its cognitive-focused sibling Semax, another intranasal Russian heptapeptide with the same small-but-real evidence pattern and the same unapproved U.S. status. If you are mapping either against better-studied options before committing to a regimen, our peptide evidence matrix grades each peptide by the strength of its human data, and our peptide therapy provider comparison covers the legitimate telehealth landscape for the molecules that actually have it.

The honest bottom line

The truthful answer to “how much Selank” is that there is no validated dose to give you. What the literature does support is the form and shape of how it has been used: an intranasal spray, dosed in divided amounts through the day, as a short course of roughly one to two weeks rather than an indefinite daily regimen.^[5] The intranasal route is the one the research found best delivers the peptide to the brain.^[3] Everything beyond that — the exact micrograms, the “N-acetyl Selank amidate” upgrade, the injection variants — is a convention circulated outside any regulatory approval, attached to products of unverified content. Describing that landscape honestly is fair; presenting a number as a prescription would not be. Anyone considering Selank is best served by talking it through with a qualified clinician who can weigh their situation against evidence that is, for now, genuinely thin.